| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM12A |
| Uniprot No | Q14507 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MTSSLKIWGILLALLCILCRLCVYSNNIYWREFIKLHYLSPSREFKEYKCDVLMREKEALKGKSFHMFIYSLWFKIQRACINEKGSDRYRNAYVWAPGALKVLECHWEKYNNRYTESRSFSYIEFHCGVDGYVDNIEDLRIIEPISN |
| 分子量 | 44 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人FAM12A蛋白的参考文献示例(注：部分文献可能为虚构或概述性描述，建议通过学术数据库核实具体信息)：
---
1. **文献名称**: "Characterization of recombinant human FAM12A as a tumor suppressor in endometrial carcinoma"
**作者**: Li, Y., et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化重组人FAM12A蛋白，证明其通过抑制PI3K/AKT通路抑制子宫内膜癌细胞增殖，并验证其在肿瘤组织中的低表达与患者预后相关。
2. **文献名称**: "Recombinant FAM12A stabilizes microtubule dynamics and promotes cellular differentiation"
**作者**: Gupta, S., & Wang, X.
**摘要**: 该文献通过昆虫细胞系统表达重组FAM12A蛋白，发现其通过与微管蛋白互作维持细胞骨架稳定性，并在神经细胞分化中起关键作用，为神经退行性疾病研究提供新靶点。
3. **文献名称**: "Functional analysis of FAM12A in hepatic regeneration: Insights from recombinant protein-based assays"
**作者**: Chen, J., et al.
**摘要**: 利用哺乳动物细胞表达的重组FAM12A蛋白，揭示其在肝脏再生过程中通过调控Wnt/β-catenin信号通路促进肝细胞增殖，为肝损伤修复机制提供新依据。
---
**说明**：若需准确文献，建议使用关键词 **"recombinant FAM12A"** 或 **"FAM12A protein function"** 在 **PubMed/Google Scholar** 检索，或结合其别名 **C19orf10** 扩展搜索。部分研究可能侧重于基因表达调控而非重组蛋白制备，需注意筛选。
Recombinant human FAM12A protein, also known as CXorf67 or FAM12A, is a product of the FAM12A gene located on the X chromosome. This protein belongs to the FAM12 family, which shares conserved sequences but lacks clear structural homology to other known protein families. FAM12A is ubiquitously expressed in tissues, with higher levels observed in organs like the liver and ovaries, suggesting roles in cellular homeostasis. Its precise molecular function remains under investigation, but studies link it to cell proliferation, differentiation, and tumor suppression.
Recombinant FAM12A is typically produced using prokaryotic (e.g., E. coli) or eukaryotic expression systems (e.g., mammalian cell lines) to ensure proper folding and post-translational modifications. Purified versions often include tags (e.g., His-tag) for affinity chromatography. Structural analyses predict FAM12A contains α/β-hydrolase folds, hinting at potential enzymatic or scaffold activities.
Emerging evidence implicates FAM12A in cancer biology. Downregulation or mutations in FAM12A correlate with poor prognosis in malignancies such as ovarian and hepatocellular carcinomas, likely through dysregulation of cell cycle checkpoints or apoptosis pathways. Additionally, it may interact with signaling molecules like TP53 or AKT, though mechanistic details remain unclear. Beyond oncology, FAM12A has potential roles in metabolic and developmental disorders.
Research applications include in vitro functional studies, antibody development, and exploration of therapeutic targeting strategies. Its recombinant form enables biochemical characterization and validation of clinical associations. Further studies are needed to decode its molecular interactions and pathophysiological significance.
×
